Heidi raises $100M Series C at $900M valuation to scale AI for clinicians
What's the deal? Heidi, an AI platform for clinicians, has closed a US$100 million Series C led by BlackbirdDealroom has a profile for this one. Try Dealroom → at a US$900 million valuation. Existing backers Phoenix Court, Point72 Private Investments, and Headline also joined. Alongside the equity round, Heidi secured a US$240 million growth investment led by General Catalyst's Customer Value Fund, bringing total new funding to US$340 million.
What's the endgame? Heidi wants to move its tools beyond documentation into "supervised action" — AI that completes clinical work under a doctor's oversight. The money funds deeper adoption in health systems and the regulatory and safety foundations those capabilities need.
Why now? The world faces a projected shortfall of 11 million health workers by 2030. "That's the shift we're now making: from documenting care to helping clinicians act on it," said co-founder and chief executive officer Dr. Thomas Kelly.
By the numbers: Heidi's platform has supported more than 175 million patient visits, up from 73 million at its Series B, and over 67 million clinical hours. Annual recurring revenue grew from US$1 million to US$50 million in two years. It is used across 190 countries and 110 languages.
Who's using it? Enterprise adoption spans Beth Israel Lahey HealthDealroom has a profile for this one. Try Dealroom → in the US and NHS England MidlandsDealroom has a profile for this one. Try Dealroom →, which named Heidi sole supplier in what it calls the largest clinical AI procurement in NHS history. In New Zealand, Heidi is deployed across every emergency department.
The signal: At US$100 million, Heidi's Series C ranks near the top of Australian health-sector rounds at this stage — above the 90th percentile of comparable deals. The raise reflects growing investor conviction that AI can address widening gaps between clinical demand and capacity.
Read more: businesswire.com
Image credit: Heidi
